<< Back To Search

High Dose Ascorbic Acid for Plasma Cell Disorders

Notify the Multiple Myeloma Research Foundation You Are Interested In This Trial


Third Opinion Trial Synopsis:
This is a study that will test a new treatment for people with a type of cancer called multiple myeloma. The treatment uses a low dose of a drug called melphalan and a high dose of vitamin C. The study will focus on whether the treatment is safe and whether it works better than other treatments that did not work before.
*Third Opinion AI Generated Synopsis

Trial Summary
This is a Phase I single-arm open-label clinical study primarily assessing the safety and secondarily, the relative efficacy of low dose melphalan + high dose ascorbate acid (HDAA) in relapsed refractory patients with multiple myeloma.

Locations & Contact

Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Is There Anything Else You Would Like To Share?